Top news
In two Phase 3 trials, DRM01 failed to meet any of its study objectives, pushing the biotech to discontinue further development of the drug.
|
The big biotech inked a development deal with Vividion Therapeutics to discover small molecule drugs for a range of therapeutic areas.
|
Minnesota Senator Tina Smith asked five top pharmaceutical companies whether the benefits from the recent tax cut would be used to help lower drug costs.
|
The demand for pre-filled syringes is escalating rapidly. for additional insight into the advantages of automated vs. manual assembly and labeling.
|
Treatment with trilaciclib significantly improved immune system function for small cell lung cancer patients, building a stronger profile for G1's main drug.
|
Feature Story
Research into the clinical applications of the microbiome is gathering steam, spurring new investment and raising hopes for novel therapeutics.
|
The FDA is expected to decide on approval of lanadelumab by August, potentially adding to Shire's existing HAE portfolio.
|
BROUGHT TO YOU BY – DTC Perspectives
Join the 18th Annual DTC National Conference
The 2018 DTC National agenda will feature the latest insights, research, and case studies on all aspects of DTC pharmaceutical marketing. See several innovative presentations around behaviorism and neuroscience, and gain insights from advanced research revealed for the first time at the DTC National. Learn more
What We're Reading
 Reuters
|
 Chemical & Engineering News
|
 Regulatory Focus
|
 PBS
|
Dive Into a Topic
|
